Last updated: February 20, 2026
What Is the Product Associated with NDC 00093-5986?
NDC 00093-5986 corresponds to Truvada (emtricitabine and tenofovir disoproxil fumarate), a fixed-dose combination used for HIV treatment and pre-exposure prophylaxis (PrEP). Approved by the FDA for HIV management in 2004, it is marketed by Gilead Sciences.
Market Overview
Global HIV Market
- The global HIV therapeutics market reached approximately $30 billion in 2022.
- The U.S. accounted for roughly 40% of the market, driven by high diagnosis rates and extensive PrEP uptake.
- The PrEP segment has grown rapidly, with an estimated approximate compound annual growth rate (CAGR) of 20% from 2018 to 2022.
Key Competitors
- Gilead Sciences (Truvada, Descovy)
- MSD (Merck & Co.) (Isentress)
- ViiV Healthcare (Cabotegravir)
Gilead dominates the PrEP market with over 80% market share in the U.S.
Patent and Regulatory Status
- Gilead's patent for Truvada expired in 2020, leading to increased generic competition.
- The FDA approved generic versions from multiple manufacturers in 2021.
- Patent challenges and litigation continue, but generics have entered the market.
Price Trends and Projections
Current Pricing
- Brand-name Truvada costs approximately $1,800 to $2,000 per month retail in the U.S.
- Generic formulations are priced between $600 and $800 per month.
- Insurance coverage and assistance programs significantly influence out-of-pocket costs.
| Price Element |
Cost (USD) |
| Brand Truvada |
$1,800 - $2,000/month |
| Generic versions |
$600 - $800/month |
| Federal rebate programs |
Reduce patient cost by up to 80% |
Future Price Projections (2023–2028)
Based on market dynamics, patent status, and manufacturing trends:
- Generic competition will sustain prices at or below $500 per month for the next 3–5 years.
- Brand Truvada may see slight price reductions, potentially around $1,500 per month by 2025, as generics expand market share.
- Market consolidation and increased access could lower prices further, especially with Medicaid and Medicare negotiations.
Factors Impacting Pricing
- Patent litigations: Delay or accelerate generic competition.
- Manufacturing costs: Decrease with technological advances.
- Insurance reimbursement policies: Drive market adoption and price sensitivity.
- Regulatory changes: Allow entry of biosimilars or alternative formulations.
- Public health initiatives: Expand PrEP access, possibly influencing price negotiations.
Market Growth Drivers and Risks
Drivers
- Increasing HIV prevalence in key regions.
- Growing awareness and acceptance of PrEP.
- Expanded insurance coverage.
- Patent expirations fostering generics.
Risks
- Regulatory hurdles for new formulations.
- Pricing pressures from biosimilars or alternative therapies.
- Political or policy changes affecting drug affordability programs.
- Competition from new HIV drugs with better efficacy or tolerability.
Strategic Implications
Manufacturers should prioritize cost reduction through generic expansion, maintain regulatory agility to defend market share, and focus on patient access programs. Investors need to monitor patent litigation outcomes and manufacturers' capacity to scale generic production.
Key Takeaways
- The drug matching NDC 00093-5986 is Truvada, a key player in HIV treatment and prevention.
- The market has shifted towards generics since patent expiration in 2020.
- Prices for generic versions are expected to stabilize around $600–$800, with potential decreases under $500.
- The market continues to grow, driven by increased PrEP adoption and HIV prevalence.
- Patent litigation and regulatory environments will significantly influence future pricing and market share.
FAQs
Q1: When did patent expiration allow for generic versions of Truvada?
A1: Patent expiration occurred in 2020, facilitating generic entry starting in 2021.
Q2: How have prices changed since generic versions entered the market?
A2: Prices have decreased from approximately $1,800–$2,000 to $600–$800 per month, with further declines expected.
Q3: What are the main competitors to Truvada in PrEP?
A3: Descovy (Gilead), Cabotegravir (ViiV Healthcare), and others are competing in the PrEP space.
Q4: How might future regulations impact the market?
A4: Policy changes favoring biosimilar and generic approvals, or new HIV treatment guidelines, could influence prices and market dynamics.
Q5: What is the outlook for market growth of PrEP drugs?
A5: The PrEP market is projected to expand at a CAGR of around 15–20% over the next five years.
References
- IQVIA. (2023). Global HIV Therapeutics Market Report.
- Gilead Sciences. (2022). Quarterly Earnings and Market Share Data.
- FDA. (2022). Approved Drugs and Patent Status.
- Statista. (2023). PrEP Usage and Market Trends.
- Centers for Disease Control and Prevention. (2022). HIV Surveillance Data.
